Repopulation of tumour cells between cycles of chemotherapy: A neglected factor

Lancet Oncology

Volumn 1, Issue 2, 2000, Pages 86-93

  Davis, Alison J ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL DIVISION; HUMAN; NEOPLASM; PATHOLOGY; REVIEW; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034309182     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00019-X     Document Type: Review

References (55)

1. Wheldon TE, Michalowski AS, Kirk J. The effect of irradiation on function in self-renewing normal tissues with differing proliferative organisation. Br J Radiol 1982; 55: 759-66.
2. Field SB, Michalowski A. Response of normal tissues: implications for clinical radiotherapy. New York: Masson, 1983.
3. Potten CS, Hendry JH. Cytotoxic insult to tissue. Effects on cell lineages. Edinburgh, Churchill Livingstone, 1983.
4. Denekamp J. Changes in the rate of repopulation during multifraction irradiation of mouse skin. Br J Radiol 1983; 46: 381-87.
5. Moore MA. Hematopoietic reconstruction: new approaches. Clin Cancer Res 1995; 1: 3-9.
6. Messner HA. Assessment and characterization of hemopoietic stem cells. Stem Cells Suppl 13: 1995; 3: 13-18.
7. Fauser AA, Messner HA. Proliferative state of human pluripotent hemopoietic progenitors (CFU- GEMM) in normal individuals and under regenerative conditions after bone marrow transplantation. Blood 1979; 54: 1197-200.
8. Abe Y, Urano M, Kenton LA, et al. The accelerated repopulation of a murine fibrosarcoma, FSA-II, during the fractionated irradiation and the linear-quadratic model. Int J Radiat Oncol Biol Phys 1991; 21: 1529-34.
9. Suit H, Urano M. Repair of sublethal radiation injury in hypoxic cells of a C3H mouse mammary carcinoma. Radiat Res 1969; 37: 423-34.
10. Hermens AF, Barendsen GW. Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur J Cancer 1967; 3: 361-69.
11. Begg AC, Hofland I, Kummermehr J. Tumour cell repopulation during fractionated radiotherapy: correlation between flow cytometric and radiobiological data in three murine tumours. Eur J Cancer 1991; 27: 537-43.
12. 50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys 1991; 21: 1195-202.
13. Maciejewski B, Preuss-Bayer G, Trott KR. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983; 9: 321-28.
14. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-46.
15. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol 1991; 22: 161-66.
16. Fyles A, Keane TJ, Barton M, et al. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992; 25: 273-79.
17. Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993; 25: 391-97.
18. Norin T, Onyango J. Radiotherapy in Burkitt's lymphoma: conventional or superfractionated regime - early results. Int J Radiat Oncol Biol Phys 1977; 2: 399-406.
19. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 1997; 350: 161-65,
20. Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-36.
21. Saunders MI, Dische S, Barrett A, et al. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer 1996; 73: 1455-62.
22. Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 1997; 43: 47-51.
23. Skladowski K, Maciejewski B, Golen M, et al. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 2000; 55: 101-10.
24. Kinsella TJ, Gould MN, Mulcahy RT, et al. Keynote address: integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors. Int J Radiat Oncol Biol Phys 1991; 20: 295-302.
25. Ezekiel MP, Bonner JA, Robert F, et al. Phase I trial of chimerized anti-epidermal growth factor receptor (Anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc Am Soc Clin Oncol 1999; 18: 1501.
26. Stephens TC, Peacock JH. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 1977; 36: 313-21.
27. Rosenblum ML, Gerosa MA, Dougherty DV, et al. Improved treatment of a brain-tumor model. Part 1: advantages of single- over multiple-dose BCNU schedules. J Neurosurg 1983; 58: 177-82.
28. Rosenblum ML, Knebel KD, Vasquez DA, et al. In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy. Cancer Res 1976; 36: 3718-25.
29. Milas L, Nakayama T, Hunter N, et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 1994; 30: 247-53.
30. Gohde W, Meistrich M, Meyn R, et al. Cell-cycle phase-dependence of drug-induced cycle progression delay. J Histochem Cytochem 1979; 27: 470-73.
31. Walter J, Maurer-Schultze B. Tumor cell recruitment in the mouse adenocarcinoma EO 771 directly demonstrated by double labeling with [3H] - and [14C] thymidine and flow cytometry. J Cancer Res Clin Oncol 1989; 115: 53-60.
32. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988; 240: 177-84.
33. Durand RE. Multicell spheroids as a model for cell kinetic studies. Cell Tissue Kinet 1990; 23: 141-59.
34. Durand RE, Vanderbyl SL. Tumor resistance to therapy: a genetic or kinetic problem? Cancer Commun 1989; 1: 277-83.
35. Durand RE, Vanderbyl SL. Schedule dependence for cisplatin and etoposide multifraction treatments of spheroids. J Natl Cancer Inst 1990; 82: 1841-45.
36. Bourhis J, Wilson G, Wibault P, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994; 104: 468-72.
37. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351 suppl 2: SII9-16.
38. Withers HR. From bedside to bench and back. New York: Academic Press, 1991.
39. Castiglione-Gertsch M, Tattersall M, Hacking A, et al. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 1997; 33: 2321-25.
40. Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986; 58: 1411-17.
41. Buzdar AU, Legha SS, Hortobagyi GN, et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 1981; 47: 2798-802.
42. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823-26
43. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev 1995; 16: 559-89.
44. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47: 87-98.
45. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-48.
46. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536-39.
47. Chakrabarty S, Rajagopal S, Huang S. Expression of antisense epidermal growth factor receptor RNA downmodulates the malignant behavior of human colon cancer cells. Clin Exp Metastasis 1995; 13: 191-95.
48. De Giovanni C, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res 1996; 56: 3898-901.
49. Modjtahedi H, Eccles S, Box G, et al. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 1993; 67: 254-61.
50. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-84.
51. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988; 2: 273-77.
52. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988; 2: 387-94.
53. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment, targeting simply Ras? Biochim Biophys Acta 1997; 1333: F51-71.
54. Tunggal JK, Cowan DS, Shaikh H, et al. Penetration of anticancer drugs through solid tissue. a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999; 5: 1583-86.
55. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.